Bicara Therapeutics Inc. · NASDAQ (us_market)
Healthcare · Biotechnology · United States
Bicara Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines a clinically validated epidermal growth factor receptor directed monoclonal antibody bound to human transforming growth factor beta for the treatment of solid tumors. The company was incorporated in 2018 and is based in Boston, Massachusetts.
| Event Period | Drawdown | Buy Point (Bottom) | Sell Point (Peak) | ticker.setupCols.buyScore | ticker.setupCols.sellScore | Max Return | Algo Return |
|---|---|---|---|---|---|---|---|
DROP2025-12-10$19.11 RISE2026-02-12$14.06 PEAK2026-04-17$24.01 128d | -26.4% 64d | Missed | Missed | — | — | +70.8% 64d | Missed |
DROP2025-12-10$19.11 RISE2026-01-05$16.11 PEAK2026-04-01$20.50 112d | -15.7% 26d | Missed | Missed | — | — | +27.3% 86d | Missed |
DROP2025-10-15$18.81 RISE2025-11-10$13.93 PEAK2025-12-10$19.11 56d | -25.9% 26d | Missed | Missed | — | — | +37.2% 30d | Missed |
DROP2025-05-22$15.66 RISE2025-09-19$10.44 PEAK2025-12-10$19.11 202d | -33.3% 120d | Missed | Missed | — | — | +83.0% 82d | Missed |
DROP2025-05-22$15.66 RISE2025-08-11$9.99 PEAK2025-10-15$18.81 146d | -36.2% 81d | Missed | Missed | — | — | +88.3% 65d | Missed |
DROP2025-03-07$16.55 RISE2025-06-27$8.71 PEAK2025-09-09$12.46 186d | -47.4% 112d | Missed | Missed | — | — | +43.1% 74d | Missed |
DROP2024-12-09$21.14 RISE2025-04-08$9.37 PEAK2025-05-22$15.66 164d | -55.7% 120d | Missed | Missed | — | — | +67.1% 44d | Missed |
DROP2024-09-17$27.07 RISE2025-01-24$11.61 PEAK2025-03-07$16.55 171d | -57.1% 129d | Missed | Missed | — | — | +42.6% 42d | Missed |
DROP2024-09-17$27.07 RISE2024-10-10$19.00 PEAK2024-11-05$25.19 49d | -29.8% 23d | Missed | Missed | — | — | +32.6% 26d | Missed |
Bicara Therapeutics (NASDAQ:BCAX) said new data to be presented at the 2026 American Society of Clinical Oncology annual meeting support the clinical profile of ficerafusp alfa, also referred to by the company as Ficara, in first-line recurrent or metastatic HPV-negative head and neck cancer. On an
Bicara Therapeutics Inc. (BCAX) Discusses New Clinical Data on Investigational Therapy for HPV Negative Head and Neck Cancer at ASCO May 22, 2026 8:30 AM...
At a median follow-up of three years, 1500mg of ficerafusp alfa weekly in combination with pembrolizumab demonstrated an estimated 31% overall survival, approximately doubling OS compared to a
Recent trading performance and context Bicara Therapeutics (BCAX) has drawn investor attention after a choppy stretch in the stock, with shares down about 5% over the past day and roughly 16% over the past week. See our latest analysis for Bicara Therapeutics. Set against a 37% 3 month share price return and a 26.82% 1 year total shareholder return, the recent pullback suggests momentum has cooled as investors reassess Bicara Therapeutics at its latest US$19.29 share price. If you are...
Recent trading performance and context Bicara Therapeutics (BCAX) has drawn investor attention after a choppy stretch in the stock, with shares down about 5% over the past day and roughly 16% over the past week. See our latest analysis for Bicara Therapeutics. Set against a 37% 3 month share price return and a 26.82% 1 year total shareholder return, the recent pullback suggests momentum has cooled as investors reassess Bicara Therapeutics at its latest US$19.29 share price. If you are...
This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and institutions.
This clinical-stage biotech develops bifunctional antibody therapies targeting solid tumors for oncology providers and institutions.
Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors.
Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors.
Bicara Therapeutics (NASDAQ:BCAX) said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development strategy and competitive positioning at the Bank of America Healthcare Conference. Ryan Kohlhepp of
Bicara Therapeutics (NASDAQ:BCAX) said its lead cancer drug candidate, ficerafusp alfa, remains on track for pivotal data in head and neck cancer in mid-2026, as the company outlined its development strategy and competitive positioning at the Bank of America Healthcare Conference. Ryan Kohlhepp of
Bicara Therapeutics Inc. (BCAX) Bank of America Global Healthcare Conference 2026 May 13, 2026 12:20 PM EDTCompany ParticipantsRyan Cohlhepp - President,...
Presenter SpeechTazeen Ahmad Good morning, everybody. Welcome back to the Bank of America Healthcare Conference. I'm Tazeen Ahmad, one of the senior biotech analysts here at the bank. It is my...
BOSTON, May 13, 2026 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies to patients with solid tumors, today announced that, effective May 8, 2026, it awarded an inducement grant to Christopher Sarchi under Bicara’s 2026 Inducement Plan as a material inducement to his commencement of employment as Bicara’s Chief Commercial Officer. Mr. Sarchi received a non-qualified stock option to p
Goldman Sachs analyst Richard Law maintains Bicara Therapeutics (NASDAQ:BCAX) with a Neutral and raises the price target from $16 to $18.
Morgan Stanley analyst Judah Frommer maintains Bicara Therapeutics (NASDAQ:BCAX) with a Overweight and raises the price target from $36 to $37.
Bicara Therapeutics Inc (BCAX) reports robust cash reserves and strategic progress in its Fortify HN01 trial, positioning Fisera for potential accelerated approval.
Bicara Therapeutics Inc (BCAX) reports robust cash reserves and strategic progress in its Fortify HN01 trial, positioning Fisera for potential accelerated approval.
Moby summary of Bicara Therapeutics Inc. Common Stock's Q1 2026 earnings call
Moby summary of Bicara Therapeutics Inc. Common Stock's Q1 2026 earnings call
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| BCAX | +0.37% | +23.65% | +29.23% | +135.14% |
| XLV | +2.97% | -5.72% | -3.44% | +12.69% |
| Alpha (stock − sector) | -2.60% | +29.36% | +32.68% | +122.45% |
| Fund | Style | Shares | Value | % of Port | Change vs. last quarter | Period |
|---|---|---|---|---|---|---|
| FidelityFMR | fundamental | 2.10M | $41.79M | 0.00% | Trimmed-37.2% | 2026-03-31 |
| StateStreet | passive | 1.42M | $28.23M | 0.00% | Trimmed-14.0% | 2026-03-31 |
| DEShaw | quant | 276.9K | $5.51M | 0.00% | Added+102.9% | 2026-03-31 |
| TwoSigma | quant | 89.9K | $1.79M | 0.00% | Trimmed-8.7% | 2026-03-31 |
| TRowePrice | fundamental | 1.38M | $27.37K | 0.00% | Trimmed-11.8% | 2026-03-31 |
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-08-11upcoming | -0.81 | — | — |
| 2026-05-11 | -0.65 | -0.93 | -42.64% |
| 2026-03-30 | -0.65 | -0.68 | -3.98% |
| 2025-11-10 | -0.53 | -0.67 | -25.53% |
| 2025-08-12 | -0.54 | -0.50 | +6.83% |
| 2025-05-13 | -0.40 | -0.68 | -70.85% |
| 2025-03-27 | -0.28 | -0.39 | -38.05% |
| 2024-11-12 | -0.50 | -1.60 | -220.00% |